Resources

Selected
  • Systematic reviews (SYSVAC)
  • Pregnant women
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

270 results found

2025 ∙ Shi, Q. Li, J. Hu, Q. Cheng, C. Yang, K. Li, X. Song, X. Chen, S. Duan, G.

Efficacy, Immunogenicity, and Safety of Pertussis Vaccine During Pregnancy: A Meta-Analysis

  • Pregnant women
  • Pertussis
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Wang, Y. Zhang, Y. Wang, J. Shi, N. Jin, H.

Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies

  • All age groups
  • Pregnant women
  • Healthcare workers
  • Influenza
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Alandijany, T. A. Qashqari, F. S.

Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia

  • All age groups
  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Nembot Fogang, B. A. Debrah, L. B. Owusu, M. Agyei, G. Meyer, J. Gmanyami, J. M. Ritter, M. Arndts, K. Adu Mensah, D. Adjobimey, T. Horauf, A. Debrah, A. Y.

Helminth Coinfections Modulate Disease Dynamics and Vaccination Success in the Era of Emerging Infectious Diseases

  • Children
  • Adolescents
  • Adults
  • Pregnant women
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Bergman, H. Henschke, N. Arevalo-Rodriguez, I. Buckley, B. S. Crosbie, E. J. Davies, J. C. Dwan, K. Golder, S. P. Loke, Y. K. Probyn, K. et al.,

Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV‐related diseases: a network meta‐analysis

  • All age groups
  • Pregnant women
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
High
2025 ∙ Yasin, R. Jiang, L. Das, J. K. Bhutta, Z. A.

Interventions to Prevent and Manage Infections in Pregnancy

  • Pregnant women
  • Tetanus
  • Influenza
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Zadeh Mehrizi, T. Ataei-Pirkooh, A. Eshrati, B. Ebrahimi Shahmabadi, H.

Investigating factors affecting the effectiveness of Gardasil 4, Cervarix, and Gardasil 9 vaccines considering the WHO regions in females: A systematic review

  • Adolescents
  • Adults
  • Pregnant women
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Gavaruzzi, T. Ceccarelli, A. Nanni, C. Vignali, C. Colonnello, V. Caserotti, M. Ricco, M. Gori, D.

Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review

  • All age groups
  • Healthcare workers
  • Pregnant women
  • Parents/caregivers
  • RSV (Respiratory syncytial virus)
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Lugowski, F. Babinska, J. Urban, A. Kacperczyk-Bartnik, J. Bartnik, P. Romejko-Wolniewicz, E. Sienko, J.

Knowledge, Attitude, and Intention to Receive the Pertussis Vaccine in Pregnant Women: A Systematic Review

  • Pregnant women
  • Pertussis
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Torres-Torres, J. Rojas-Zepeda, L. Villafan-Bernal, J. R. Martinez-Portilla, R. Espino-y-Sosa, S. Cerda-Flores, P. Moreno-Verduzco, E. R. Monroy-Munoz, I. E. Gonzalez-Guerrero, A. Y. Solis-Paredes, J. M. Duran, J. P.

Maternal RSV vaccination for infant protection: A systematic review and meta-analysis of phase 3 trials with an integrated economic evaluation

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
  • Economic aspects
  • Administration
Methodological quality (AMSTAR 2):
Critically low
Loading...